Literature DB >> 22431178

Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.

Mitsumaro Itoyama1, Masaki Hata, Koji Yamanegi, Naoko Yamada, Hideki Ohyama, Hiroshi Hirano, Nobuyuki Terada, Keiji Nakasho.   

Abstract

Expression of phenotype markers of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) in HCC and CC components of 20 combined hepatocellular and cholangiocarcinomas (CHCs) of the liver was investigated immunohistochemically. Both HCC and CC components of all CHCs expressed at least one of the CC phenotype markers [cytokeratin (CK)-7, CK-19, and carbohydrate (CA) 19-9]. HCC components in 90% of CHCs and CC components in 95% of CHCs expressed at least one of these CC phenotype markers in more than 40% of cancer cells. HCC components in all CHCs expressed at least one of the HCC phenotype markers [hepatocyte antigen (HA), α-fetoprotein (AFP), and canalicular carcinoembryonic antigen]. HCC components in 90% of CHCs and CC components in 75% of CHCs expressed HA, AFP, or both. HCC components in 75% of CHCs and CC components in 60% of CHCs expressed HA, AFP, or both in more than 10% of cancer cells. The present results show that both HCC and CC components of most of the CHCs expressed both HCC and CC phenotypes, supporting the hypothesis that CHC originates from a hepatic progenitor cell capable of differentiating into hepatocytes and cholangiocytes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22431178     DOI: 10.1007/s00795-010-0534-z

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  25 in total

1.  Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.

Authors:  Dominique Cazals-Hatem; Sandra Rebouissou; Paulette Bioulac-Sage; Olivier Bluteau; Hélène Blanché; Dominique Franco; Geneviève Monges; Jacques Belghiti; Antonio Sa Cunha; Pierre Laurent-Puig; Claude Degott; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2004-08       Impact factor: 25.083

2.  Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.

Authors:  Mina Komuta; Bart Spee; Sara Vander Borght; Rita De Vos; Chris Verslype; Raymond Aerts; Hirohisa Yano; Tetsuya Suzuki; Masanori Matsuda; Hideki Fujii; Valeer J Desmet; Masamichi Kojiro; Tania Roskams
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

3.  The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin.

Authors:  A Durnez; C Verslype; F Nevens; J Fevery; R Aerts; J Pirenne; E Lesaffre; L Libbrecht; V Desmet; T Roskams
Journal:  Histopathology       Date:  2006-08       Impact factor: 5.087

4.  Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study.

Authors:  Z D Goodman; K G Ishak; J M Langloss; I A Sesterhenn; L Rabin
Journal:  Cancer       Date:  1985-01-01       Impact factor: 6.860

5.  A clinicopathological study on combined hepatocellular and cholangiocarcinoma.

Authors:  J Taguchi; O Nakashima; M Tanaka; T Hisaka; T Takazawa; M Kojiro
Journal:  J Gastroenterol Hepatol       Date:  1996-08       Impact factor: 4.029

6.  The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver.

Authors:  T Maeda; K Kajiyama; E Adachi; K Takenaka; K Sugimachi; M Tsuneyoshi
Journal:  Mod Pathol       Date:  1996-09       Impact factor: 7.842

7.  Genetic classification of combined hepatocellular-cholangiocarcinoma.

Authors:  H Fujii; X G Zhu; T Matsumoto; M Inagaki; Y Tokusashi; N Miyokawa; T Fukusato; T Uekusa; T Takagaki; N Kadowaki; T Shirai
Journal:  Hum Pathol       Date:  2000-09       Impact factor: 3.466

8.  Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma.

Authors:  Sanjay Kakar; Trudie Muir; Linda M Murphy; Ricardo V Lloyd; Lawrence J Burgart
Journal:  Am J Clin Pathol       Date:  2003-03       Impact factor: 2.493

9.  Comparative immunohistochemical study of primary and metastatic carcinomas of the liver.

Authors:  C K Ma; R J Zarbo; H F Frierson; M W Lee
Journal:  Am J Clin Pathol       Date:  1993-05       Impact factor: 2.493

10.  Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.

Authors:  Peiguo G Chu; Shin Ishizawa; Emerald Wu; Lawrence M Weiss
Journal:  Am J Surg Pathol       Date:  2002-08       Impact factor: 6.394

View more
  5 in total

Review 1.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

Review 2.  Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review.

Authors:  Damiano Gentile; Matteo Donadon; Ana Lleo; Alessio Aghemo; Massimo Roncalli; Luca di Tommaso; Guido Torzilli
Journal:  Liver Cancer       Date:  2019-11-01       Impact factor: 11.740

3.  A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Shaffer R S Mok; Sachin Mohan; Navjot Grewal; Adam B Elfant; Thomas A Judge
Journal:  J Gastrointest Oncol       Date:  2016-08

4.  Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography.

Authors:  Rui Li; Dan Yang; Chun-Lin Tang; Ping Cai; Kuan-Sheng Ma; Shi-Yi Ding; Xiao-Hang Zhang; De-Yu Guo; Xiao-Chu Yan
Journal:  BMC Cancer       Date:  2016-02-25       Impact factor: 4.430

Review 5.  Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma.

Authors:  Shweta Gera; Mark Ettel; Gabriel Acosta-Gonzalez; Ruliang Xu
Journal:  World J Hepatol       Date:  2017-02-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.